PHARMACOGENOMICS AND ARTIFICIAL INTELLIGENCE FOR PRECISION DRUG THERAPY AND SURGICAL OUTCOME OPTIMIZATION IN PAKISTAN

Abstract

The integration of pharmacogenomics and artificial intelligence (AI) has emerged as a transformative approach in precision medicine, enabling individualized drug therapy and enhanced surgical outcome optimization through genetic profiling and predictive analytics. This study examines the synergistic role of pharmacogenomics and AI in improving therapeutic efficacy, reducing adverse drug reactions, and supporting clinical decision-making within Pakistan’s healthcare system, where precision medicine adoption remains limited. A quantitative, cross-sectional research design was employed, using structured survey data from healthcare professionals to assess the influence of pharmacogenomics, AI adoption, and healthcare system readiness on precision drug therapy and surgical outcomes. Statistical techniques, including regression analysis and structural equation modeling, were applied to evaluate relationships among variables. The findings reveal that both pharmacogenomics and AI significantly and positively influence precision drug therapy and surgical outcome optimization. AI demonstrated a stronger predictive impact on surgical outcomes, while pharmacogenomics played a dominant role in drug response optimization. However, healthcare system readiness emerged as a critical moderating constraint, limiting the full implementation of precision medicine practices in Pakistan. The study concludes that effective integration of pharmacogenomics and AI can substantially enhance clinical outcomes, but requires strengthened genomic infrastructure, AI-enabled clinical systems, and workforce capacity development in Pakistan’s healthcare sector.